Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
EXAI Exscientia
9.000+0.190+2.16%
Close
02/03 16:00 ET
9.050+0.050+0.56%
Post Mkt Price 02/03 19:43 ET
High
9.660
Open
8.740
Turnover
3.99M
Low
8.650
Pre Close
8.810
Volume
436.86K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Strong Week for Exscientia (NASDAQ:EXAI) Shareholders Doesn't Alleviate Pain of One-year Loss
Over the last month the Exscientia plc (NASDAQ:EXAI) has been much stronger than before, rebounding by 53%. But that doesn't change the reality of under-performance over the last twelve months. Th
Exscientia Says EXS4318 Drug Candidate Has Entered Phase 1 Clinical Trials in US -- Shares Rise
11:10 AM EST, 02/02/2023 (MT Newswires) -- Exscientia (EXAI) said Thursday it has entered phase 1 clinical trials in the US for EXS4318, a compound designed by the company and in-licensed by Bristol-M
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
- EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - - Exscientia invented a potentially first-in-class potent and selective
Quoin, F-star Top Healthcare Gainers; Evelo, Taysha Lead Losers' Pack
SMCI, HA and RXT Are Among After Hour Movers
Exscientia (NASDAQ:EXAI) Stock Price Down 5.8%
Exscientia plc (NASDAQ:EXAI – Get Rating)'s stock price was down 5.8% on Monday . The stock traded as low as $6.31 and last traded at $6.32. Approximately 35,553 shares were traded during trading, a
Comparing Exscientia (NASDAQ:EXAI) & SOPHiA GENETICS (NASDAQ:SOPH)
Exscientia (NASDAQ:EXAI – Get Rating) and SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses base
Exscientia Plc (NASDAQ:EXAI) Short Interest Down 13.6% in December
Exscientia plc (NASDAQ:EXAI – Get Rating) was the recipient of a large decline in short interest in December. As of December 30th, there was short interest totalling 1,590,000 shares, a decline of 1
Exscientia Plc (NASDAQ:EXAI) Short Interest Update
Exscientia plc (NASDAQ:EXAI – Get Rating) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 1,840,000 shares,
Exscientia Plc's (NASDAQ:EXAI) Market Cap Touched US$613m Last Week, Benefiting Both Individual Investors Who Own 57% as Well as Institutions
A look at the shareholders of Exscientia plc (NASDAQ:EXAI) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 57% ownership. In
Company Overview
More
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.
CEO： Mr. Andrew L. Hopkins, D.Phil.
Market： NASDAQ
Listing Date： 10/01/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet